News
Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.
Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.
18h
GlobalData on MSNMixed results from Roche’s mAb in COPDRoche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...
Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.
Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...
Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...
Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...
When Chloe Tatton boarded a flight to relocate to Dubai early last year, she hoped the change of climate might help ease her ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...
Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge ...
A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that deuruxolitinib (Leqselvi; Sun Pharma) at a dosage of 12 mg twice daily for 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results